Methods
We carried out a retrospective analysis of hospital records of children
who received Peg-GCSF for PBSC mobilization between May 2016 to
September 2020 in our unit. All children received single subcutaneous
dose of Peg-GCSF 100 microgram/kg 24-48 hours after completion of
mobilisation chemotherapy and proceeded to PBSC harvest once CD34 count
was >10/microliter in the peripheral blood. All PBSC
collection were performed on COMTEC (Fresenius Kabi, Germany) apheresis
machine. The product sample was taken at the end of PBSC collection from
the apheresis collection bag for enumerating CD34 count in the final
product. The stem cells were cryopreserved for autologous transplant.
Patients were monitored for possible adverse effects of Peg-GCSF viz.
bone pain, headache, skin rash, transient hypotension, splenic
enlargement, capillary leak syndrome characterized by puffiness,
difficulty in breathing, decreased urine output (1,6,13,15).